Sagent Pharmaceuticals Announces the Launch of Octreotide Acetate Injection

SCHAUMBURG, Ill., Dec. 23, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Octreotide Acetate Injection, a Somatostatin Analog, in five vial presentations. According to IMS, for the 12 months ending October 2013, the US market for Octreotide Acetate Injection approximated $45 million. As with all products in Sagent's portfolio, Octreotide features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

About Octreotide Acetate Injection

Octreotide Acetate Injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.

The package insert, available at, contains the indications, boxed warning, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 jsinger@sagentpharma.comSource:Sagent Pharmaceuticals, Inc.